Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance.
Homoharringtonine
Mcl-1
breast cancer
protein synthesis
translation inhibitor
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
11
2018
accepted:
01
04
2019
entrez:
21
6
2019
pubmed:
21
6
2019
medline:
21
6
2019
Statut:
epublish
Résumé
Triple negative breast cancers (TNBC) without
Types de publication
Journal Article
Langues
eng
Pagination
1043-1060Déclaration de conflit d'intérêts
None.
Références
Am J Hematol. 2004 Jul;76(3):199-204
pubmed: 15224352
Mol Cancer Ther. 2006 Mar;5(3):723-31
pubmed: 16546987
Br J Cancer. 2006 Aug 7;95(3):253-9
pubmed: 16847470
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
J Clin Oncol. 2008 Mar 10;26(8):1275-81
pubmed: 18250347
Curr Mol Med. 2008 Mar;8(2):138-47
pubmed: 18336294
Int J Hematol. 2008 Jun;87(5):507-515
pubmed: 18415656
Clin Breast Cancer. 2009 Feb;9(1):29-33
pubmed: 19299237
Blood. 2011 Jan 6;117(1):156-64
pubmed: 20971952
Cell Death Differ. 2011 Sep;18(9):1414-24
pubmed: 21415859
Leukemia. 2011 Jun;25(6):985-94
pubmed: 21468038
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
Biomed Chromatogr. 2012 May;26(5):545-7
pubmed: 21830228
J Biol Chem. 2012 Mar 23;287(13):10224-35
pubmed: 22311987
Cancer Chemother Pharmacol. 2013 Jan;71(1):35-41
pubmed: 23053254
Br J Cancer. 1990 Jul;62(1):8-13
pubmed: 2390488
Oncologist. 2014 Jan;19(1):94-9
pubmed: 24309980
Cancer Discov. 2014 Feb;4(2):232-45
pubmed: 24356096
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):261-6
pubmed: 24363325
J Hematol Oncol. 2014 Jan 03;7:2
pubmed: 24387717
Clin Cancer Res. 2014 Apr 1;20(7):1735-40
pubmed: 24501394
Oncologist. 2014 Aug;19(8):805-13
pubmed: 24969162
Wiley Interdiscip Rev RNA. 2015 Jan-Feb;6(1):1-15
pubmed: 25264217
Nat Rev Drug Discov. 2015 Apr;14(4):261-78
pubmed: 25743081
FEBS Lett. 1989 Nov 6;257(2):254-6
pubmed: 2583270
Cell Death Differ. 2015 Dec;22(12):2098-106
pubmed: 26045046
Clin Breast Cancer. 2015 Dec;15(6):473-481.e3
pubmed: 26051240
Sci Rep. 2015 Jul 13;5:8477
pubmed: 26166037
FEBS J. 2016 Jul;283(14):2661-75
pubmed: 26293580
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Expert Opin Ther Pat. 2017 Feb;27(2):163-178
pubmed: 27744724
Nature. 2016 Oct 27;538(7626):477-482
pubmed: 27760111
Mol Carcinog. 2017 May;56(5):1383-1394
pubmed: 27864890
Exp Biol Med (Maywood). 2017 May;242(9):996-1004
pubmed: 28056549
Sci Transl Med. 2017 Aug 2;9(401):null
pubmed: 28768804
Front Oncol. 2017 Jul 26;7:158
pubmed: 28798901
Clin Breast Cancer. 2018 Jun;18(3):e393-e399
pubmed: 28801156
Asia Pac J Clin Oncol. 2018 Feb;14(1):32-39
pubmed: 28815913
PLoS One. 2017 Aug 17;12(8):e0183578
pubmed: 28817737
Cell Metab. 2017 Oct 3;26(4):633-647.e7
pubmed: 28978427
Curr Opin Genet Dev. 2018 Feb;48:104-111
pubmed: 29179096
Cell Death Dis. 2018 Jan 16;9(2):19
pubmed: 29339815
Biomed Pharmacother. 2018 Jul;103:435-442
pubmed: 29679903
ESMO Open. 2018 May 3;3(Suppl 1):e000357
pubmed: 29765774
Sci Rep. 2018 May 29;8(1):8216
pubmed: 29844447
Tumori. 1986 Aug 31;72(4):395-8
pubmed: 3532469
Nature. 1985 Mar 28-Apr 3;314(6009):366-9
pubmed: 3885045
Cancer Treat Rep. 1986 Mar;70(3):375-9
pubmed: 3955548
Yao Xue Xue Bao. 1994;29(9):667-72
pubmed: 7900538